Table 21, Summary of included studies for inpatient versus outpatient subgroup analysis for comparison 3d SNRIs versus SSRIs - Service delivery Models and settings for delivery of services

Table 21Summary of included studies for inpatient versus outpatient subgroup analysis for comparison 3d SNRIs versus SSRIs

Study	Population	Intervention	Comparison	Comments
Inpatient setting (K=4, N=476)
Clerc 1994 RCT France & Belgium	Inpatient N=68 Baseline severity: More severe Mean age (years): 51.3 Sex (% female): 68 Ethnicity (% BME): NR	Venlafaxine 200mg/day	Fluoxetine 40mg/day	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Depression symptoms change score Response
Hwang 2004 RCT Taiwan	Inpatient N=105 Baseline severity: More severe Mean age (years): 65.1 Sex (% female): 58 Ethnicity (% BME): NR	Venlafaxine 75-150mg/day	Paroxetine 20-40mg/day	Treatment duration (weeks): 4 Outcome (for inpatient versus outpatient subgroup analysis): Response
Sheehan 2009ba RCT US	Inpatient N=194 Baseline severity: More severe Mean age (years): 39.7 Sex (% female): 59 Ethnicity (% BME): NR	Venlafaxine 225-375mg/day	Fluoxetine 60-80mg/day	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Depression symptoms change score Remission Response
Tzanakaki 2000 RCT Greece & Italy	Inpatient N=109 Baseline severity: More severe Mean age (years): 48 Sex (% female): 79 Ethnicity (% BME): NR	Venlafaxine 225mg/day	Fluoxetine 60mg/day	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Remission Response
Outpatient setting (K=32, N=6,238)
Allard 2004 RCT Sweden & Denmark	Outpatient N=151 Baseline severity: More severe Mean age (years): 73 Sex (% female): 80 Ethnicity (% BME): NR	Venlafaxine 75-150mg/day	Citalopram 10-20mg/day	Treatment duration (weeks): 22 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Depression symptoms change score Remission Response
Alves 1999 RCT Portugal	Outpatient N=87 Baseline severity: More severe Mean age (years): 43.7 Sex (% female): 92 Ethnicity (% BME): NR	Venlafaxine 75-150mg/day	Fluoxetine 20-40mg/day	Treatment duration (weeks): 12 Outcomes (for inpatient versus outpatient subgroup analysis): Remission Response
Bielski 2004 RCT US	Outpatient N=202 Baseline severity: More severe Mean age (years): 37.4 Sex (% female): 58 Ethnicity (% BME): 25	Venlafaxine 225mg/day	Escitalopram 20mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission Response
Casabona 2004 RCT Country NR	Outpatient N=114 Baseline severity: More severe Mean age (years): NR Sex (% female): 77 Ethnicity (% BME): NR	Venlafaxine 75mg/day	Paroxetine 20mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Remission Response
Chang 2015 RCT Taiwan	Outpatient N=112 Baseline severity: More severe Mean age (years): 39.7 Sex (% female): 73 Ethnicity (% BME): NR	Venlafaxine 75-225mg/day	Fluoxetine 20-80mg/day	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Depression symptoms change score
Costa 1998 RCT Argentina, Brazil, Chile, Colombia, Uruguay, & Venezuela	Outpatient N=382 Baseline severity: More severe Mean age (years): 40.2 Sex (% female): 79 Ethnicity (% BME): NR	Venlafaxine 75-150mg/day	Fluoxetine 20-40mg/day	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Depression symptoms change score Remission Response
DeNayer 2002 RCT Belgium	Outpatient N=146 Baseline severity: More severe Mean age (years): 42.8 Sex (% female): 68 Ethnicity (% BME): NR	Venlafaxine 75-150mg/day	Fluoxetine 20-40mg/day	Treatment duration (weeks): 12 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission Response
Detke 2004a RCT US	Outpatient N=274 Baseline severity: More severe Mean age (years): 43.3 Sex (% female): 72 Ethnicity (% BME): 0	Duloxetine 80mg/day or 120mg/day	Paroxetine 20mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission Response
Diaz-Martinez 1998 RCT Mexico	Outpatient N=145 Baseline severity: More severe Mean age (years): NR Sex (% female): 72 Ethnicity (% BME): NR	Venlafaxine 75-150mg/day	Fluoxetine 20-40mg/day	Treatment duration (weeks): 8 Outcome (for inpatient versus outpatient subgroup analysis): Response
Dierick 1996 RCT Belgium, Italy, Switzerland & France	Outpatient N=314 Baseline severity: More severe Mean age (years): 43.4 Sex (% female): 65 Ethnicity (% BME): NR	Venlafaxine 75-150mg/day	Fluoxetine 20mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Depression symptoms change score Response
Eli Lilly HMAT-Aa RCT US	Outpatient N=173 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Duloxetine 80mg/day	Paroxetine 20mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission Response
Goldstein 2002a RCT US	Outpatient N=103 Baseline severity: More severe Mean age (years): 41.5 Sex (% female): 61 Ethnicity (% BME): 17	Duloxetine 40-120mg/day	Fluoxetine 20mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Remission Response
Goldstein 2004a RCT US	Outpatient N=178 Baseline severity: More severe Mean age (years): 40.5 Sex (% female): 63 Ethnicity (% BME): 21	Duloxetine 80mg/day	Paroxetine 20mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Remission Response
Hackett 1996 RCT Europe	Outpatient N=241 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR	Venlafaxine 150mg/day	Paroxetine (dose NR)	Treatment duration (weeks): 8 Outcome (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint
Heller 2009 RCT US	Outpatient N=29 Baseline severity: More severe Mean age (years): 31.9 Sex (% female): 55 Ethnicity (% BME): NR	Venlafaxine 75-300mg/day	Fluoxetine 20-80mg/day	Treatment duration (weeks): 26 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Depression symptoms change score
Jiang 2017 RCT China	Outpatient N=26 Baseline severity: More severe Mean age (years): 45.5 Sex (% female): 73 Ethnicity (% BME): NR	Duloxetine (dose NR)	Escitalopram (dose NR)	Treatment duration (weeks): 8 Outcome (for inpatient versus outpatient subgroup analysis): Response
Khan 2007 RCT US	Outpatient N=278 Baseline severity: More severe Mean age (years): 42.4 Sex (% female): 61 Ethnicity (% BME): 20	Duloxetine 60mg/day	Escitalopram 10-20mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission Response
Kornaat 2000 RCT Country NR	Outpatient N=156 Baseline severity: More severe Mean age (years): NR Sex (% female): 64 Ethnicity (% BME): NR	Venlafaxine 75-225mg/day	Fluoxetine 20-40mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Remission Response
Mehtonen 2000 RCT Finland	Outpatient N=147 Baseline severity: More severe Mean age (years): 42.6 Sex (% female): 66 Ethnicity (% BME): NR	Venlafaxine 75-150mg/day	Sertraline 50-100mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Remission Response
Montgomery 2004 RCT Denmark, Finland, France, Germany, Ireland, Spain, & Switzerland	Outpatient N=293 Baseline severity: More severe Mean age (years): 48 Sex (% female): 71 Ethnicity (% BME): NR	Venlafaxine 75-150mg/day	Escitalopram 10-20mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Remission Response
Mowla 2016 RCT Iran	Outpatient N=63 Baseline severity: More severe Mean age (years): 41.2 Sex (% female): 60 Ethnicity (% BME): NR	Duloxetine 20-60mg/day	Sertraline 50-200mg/day	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Depression symptoms change score
Nemeroff 2007a RCT US	Outpatient N=206 Baseline severity: More severe Mean age (years): 39 Sex (% female): 65 Ethnicity (% BME): 11	Venlafaxine 75-225mg/day	Fluoxetine 20-60mg/day	Treatment duration (weeks): 6 Outcomes (for inpatient versus outpatient subgroup analysis): Remission Response
Nierenberg 2007a RCT US	Outpatient N=547 Baseline severity: More severe Mean age (years): 42.2 Sex (% female): 66 Ethnicity (% BME): 24	Duloxetine 60mg/day	Escitalopram 10mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission Response
Perahia 2006a RCT Bulgaria, Croatia, Hungary, Poland, Romania, Russia, & Slovakia	Outpatient N=293 Baseline severity: More severe Mean age (years): 45.4 Sex (% female): 71 Ethnicity (% BME): 0	Duloxetine 80mg/day or 120mg/day	Paroxetine 20mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Remission Response
Rickels 2000 RCT Country NR	Outpatient N=51 Baseline severity: More severe Mean age (years): 37.4 Sex (% female): 75 Ethnicity (% BME): NR	Venlafaxine 150-225mg/day	Fluoxetine 20-40mg/day	Treatment duration (weeks): 6 Outcome (for inpatient versus outpatient subgroup analysis): Remission
Rudolph 1999a RCT US	Outpatient N=203 Baseline severity: More severe Mean age (years): 40 Sex (% female): 72 Ethnicity (% BME): NR	Venlafaxine 75-225mg/day	Fluoxetine 20-60mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Remission Response
Shelton 2006 RCT US	Outpatient N=160 Baseline severity: More severe Mean age (years): 39.3 Sex (% female): 53 Ethnicity (% BME): 17	Venlafaxine 75-225mg/day	Sertraline 50-150mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms endpoint Depression symptoms change score Remission Response
Sir 2005 RCT Australia & Turkey	Outpatient N=163 Baseline severity: More severe Mean age (years): 37 Sex (% female): 69 Ethnicity (% BME): 2	Venlafaxine 75-225mg/day	Sertraline 50-150mg/day	Treatment duration (weeks): 8 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission Response
Study F1J-MC-HMAQ-Study Group Ba RCT US	Outpatient N=119 Baseline severity: More severe Mean age (years): 39.8 Sex (% female): NR Ethnicity (% BME): NR	Duloxetine 40-120mg/day	Fluoxetine 20mg/day	Treatment duration (weeks): 10 Outcomes (for inpatient versus outpatient subgroup analysis): Depression symptoms change score Remission Response
Tylee 1997 RCT UK	Outpatient N=341 Baseline severity: More severe Mean age (years): 44.5 Sex (% female): 71 Ethnicity (% BME): NR	Venlafaxine 75mg/day	Fluoxetine 20mg/day	Treatment duration (weeks): 12 Outcomes (for inpatient versus outpatient subgroup analysis): Remission Response
VEN XR 367 (FDA)^a RCT Europe	Outpatient N=246 Baseline severity: More severe Mean age (years): NR Sex (% female): 59 Ethnicity (% BME): NR	Venlafaxine 75mg/day or 150mg/day	Paroxetine 20mg/day	Treatment duration (weeks): 8 Outcome (for inpatient versus outpatient subgroup analysis): Depression symptoms change score
Wade 2007 RCT Belgium, Canada, the Czech Republic, France, Germany, Italy, Spain, Sweden & UK	Outpatient N=295 Baseline severity: More severe Mean age (years): 43.9 Sex (% female): 72 Ethnicity (% BME): 4	Duloxetine 60mg/day	Escitalopram 20mg/day	Treatment duration (weeks): 24 Outcomes (for inpatient versus outpatient subgroup analysis): Remission Response

Study

Population

Intervention

Comparison

Comments

Inpatient setting (K=4, N=476)

Clerc 1994

RCT

France & Belgium

Inpatient

N=68

Baseline severity: More severe

Mean age (years): 51.3

Sex (% female): 68

Ethnicity (% BME): NR

Venlafaxine 200mg/day

Fluoxetine 40mg/day

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score
Response

Hwang 2004

RCT

Taiwan

Inpatient

N=105

Baseline severity: More severe

Mean age (years): 65.1

Sex (% female): 58

Ethnicity (% BME): NR

Venlafaxine 75-150mg/day

Paroxetine 20-40mg/day

Treatment duration (weeks): 4

Outcome (for inpatient versus outpatient subgroup analysis):

Response

Sheehan 2009ba

RCT

Inpatient

N=194

Baseline severity: More severe

Mean age (years): 39.7

Sex (% female): 59

Ethnicity (% BME): NR

Venlafaxine 225-375mg/day

Fluoxetine 60-80mg/day

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score
Remission
Response

Tzanakaki 2000

RCT

Greece & Italy

Inpatient

N=109

Baseline severity: More severe

Mean age (years): 48

Sex (% female): 79

Ethnicity (% BME): NR

Venlafaxine 225mg/day

Fluoxetine 60mg/day

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Remission
Response

Outpatient setting (K=32, N=6,238)

Allard 2004

RCT

Sweden & Denmark

Outpatient

N=151

Baseline severity: More severe

Mean age (years): 73

Sex (% female): 80

Ethnicity (% BME): NR

Venlafaxine 75-150mg/day

Citalopram 10-20mg/day

Treatment duration (weeks): 22

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score
Remission
Response

Alves 1999

RCT

Portugal

Outpatient

N=87

Baseline severity: More severe

Mean age (years): 43.7

Sex (% female): 92

Ethnicity (% BME): NR

Venlafaxine 75-150mg/day

Fluoxetine 20-40mg/day

Treatment duration (weeks): 12

Outcomes (for inpatient versus outpatient subgroup analysis):

Remission
Response

Bielski 2004

RCT

Outpatient

N=202

Baseline severity: More severe

Mean age (years): 37.4

Sex (% female): 58

Ethnicity (% BME): 25

Venlafaxine 225mg/day

Escitalopram 20mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission
Response

Casabona 2004

RCT

Country NR

Outpatient

N=114

Baseline severity: More severe

Mean age (years): NR

Sex (% female): 77

Ethnicity (% BME): NR

Venlafaxine 75mg/day

Paroxetine 20mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Remission
Response

Chang 2015

RCT

Taiwan

Outpatient

N=112

Baseline severity: More severe

Mean age (years): 39.7

Sex (% female): 73

Ethnicity (% BME): NR

Venlafaxine 75-225mg/day

Fluoxetine 20-80mg/day

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score

Costa 1998

RCT

Argentina, Brazil, Chile, Colombia, Uruguay, & Venezuela

Outpatient

N=382

Baseline severity: More severe

Mean age (years): 40.2

Sex (% female): 79

Ethnicity (% BME): NR

Venlafaxine 75-150mg/day

Fluoxetine 20-40mg/day

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score
Remission
Response

DeNayer 2002

RCT

Belgium

Outpatient

N=146

Baseline severity: More severe

Mean age (years): 42.8

Sex (% female): 68

Ethnicity (% BME): NR

Venlafaxine 75-150mg/day

Fluoxetine 20-40mg/day

Treatment duration (weeks): 12

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission
Response

Detke 2004a

RCT

Outpatient

N=274

Baseline severity: More severe

Mean age (years): 43.3

Sex (% female): 72

Ethnicity (% BME): 0

Duloxetine 80mg/day or 120mg/day

Paroxetine 20mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission
Response

Diaz-Martinez 1998

RCT

Mexico

Outpatient

N=145

Baseline severity: More severe

Mean age (years): NR

Sex (% female): 72

Ethnicity (% BME): NR

Venlafaxine 75-150mg/day

Fluoxetine 20-40mg/day

Treatment duration (weeks): 8

Outcome (for inpatient versus outpatient subgroup analysis):

Response

Dierick 1996

RCT

Belgium, Italy, Switzerland & France

Outpatient

N=314

Baseline severity: More severe

Mean age (years): 43.4

Sex (% female): 65

Ethnicity (% BME): NR

Venlafaxine 75-150mg/day

Fluoxetine 20mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score
Response

Eli Lilly HMAT-Aa

RCT

Outpatient

N=173

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Duloxetine 80mg/day

Paroxetine 20mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission
Response

Goldstein 2002a

RCT

Outpatient

N=103

Baseline severity: More severe

Mean age (years): 41.5

Sex (% female): 61

Ethnicity (% BME): 17

Duloxetine 40-120mg/day

Fluoxetine 20mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Remission
Response

Goldstein 2004a

RCT

Outpatient

N=178

Baseline severity: More severe

Mean age (years): 40.5

Sex (% female): 63

Ethnicity (% BME): 21

Duloxetine 80mg/day

Paroxetine 20mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Remission
Response

Hackett 1996

RCT

Europe

Outpatient

N=241

Baseline severity: More severe

Mean age (years): NR

Sex (% female): NR

Ethnicity (% BME): NR

Venlafaxine 150mg/day

Paroxetine (dose NR)

Treatment duration (weeks): 8

Outcome (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint

Heller 2009

RCT

Outpatient

N=29

Baseline severity: More severe

Mean age (years): 31.9

Sex (% female): 55

Ethnicity (% BME): NR

Venlafaxine 75-300mg/day

Fluoxetine 20-80mg/day

Treatment duration (weeks): 26

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score

Jiang 2017

RCT

China

Outpatient

N=26

Baseline severity: More severe

Mean age (years): 45.5

Sex (% female): 73

Ethnicity (% BME): NR

Duloxetine (dose NR)

Escitalopram (dose NR)

Treatment duration (weeks): 8

Outcome (for inpatient versus outpatient subgroup analysis):

Response

Khan 2007

RCT

Outpatient

N=278

Baseline severity: More severe

Mean age (years): 42.4

Sex (% female): 61

Ethnicity (% BME): 20

Duloxetine 60mg/day

Escitalopram 10-20mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission
Response

Kornaat 2000

RCT

Country NR

Outpatient

N=156

Baseline severity: More severe

Mean age (years): NR

Sex (% female): 64

Ethnicity (% BME): NR

Venlafaxine 75-225mg/day

Fluoxetine 20-40mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Remission
Response

Mehtonen 2000

RCT

Finland

Outpatient

N=147

Baseline severity: More severe

Mean age (years): 42.6

Sex (% female): 66

Ethnicity (% BME): NR

Venlafaxine 75-150mg/day

Sertraline 50-100mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Remission
Response

Montgomery 2004

RCT

Denmark, Finland, France, Germany, Ireland, Spain, & Switzerland

Outpatient

N=293

Baseline severity: More severe

Mean age (years): 48

Sex (% female): 71

Ethnicity (% BME): NR

Venlafaxine 75-150mg/day

Escitalopram 10-20mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Remission
Response

Mowla 2016

RCT

Iran

Outpatient

N=63

Baseline severity: More severe

Mean age (years): 41.2

Sex (% female): 60

Ethnicity (% BME): NR

Duloxetine 20-60mg/day

Sertraline 50-200mg/day

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score

Nemeroff 2007a

RCT

Outpatient

N=206

Baseline severity: More severe

Mean age (years): 39

Sex (% female): 65

Ethnicity (% BME): 11

Venlafaxine 75-225mg/day

Fluoxetine 20-60mg/day

Treatment duration (weeks): 6

Outcomes (for inpatient versus outpatient subgroup analysis):

Remission
Response

Nierenberg 2007a

RCT

Outpatient

N=547

Baseline severity: More severe

Mean age (years): 42.2

Sex (% female): 66

Ethnicity (% BME): 24

Duloxetine 60mg/day

Escitalopram 10mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission
Response

Perahia 2006a

RCT

Bulgaria, Croatia, Hungary, Poland, Romania, Russia, & Slovakia

Outpatient

N=293

Baseline severity: More severe

Mean age (years): 45.4

Sex (% female): 71

Ethnicity (% BME): 0

Duloxetine 80mg/day or 120mg/day

Paroxetine 20mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Remission
Response

Rickels 2000

RCT

Country NR

Outpatient

N=51

Baseline severity: More severe

Mean age (years): 37.4

Sex (% female): 75

Ethnicity (% BME): NR

Venlafaxine 150-225mg/day

Fluoxetine 20-40mg/day

Treatment duration (weeks): 6

Outcome (for inpatient versus outpatient subgroup analysis):

Remission

Rudolph 1999a

RCT

Outpatient

N=203

Baseline severity: More severe

Mean age (years): 40

Sex (% female): 72

Ethnicity (% BME): NR

Venlafaxine 75-225mg/day

Fluoxetine 20-60mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Remission
Response

Shelton 2006

RCT

Outpatient

N=160

Baseline severity: More severe

Mean age (years): 39.3

Sex (% female): 53

Ethnicity (% BME): 17

Venlafaxine 75-225mg/day

Sertraline 50-150mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms endpoint
Depression symptoms change score
Remission
Response

Sir 2005

RCT

Australia & Turkey

Outpatient

N=163

Baseline severity: More severe

Mean age (years): 37

Sex (% female): 69

Ethnicity (% BME): 2

Venlafaxine 75-225mg/day

Sertraline 50-150mg/day

Treatment duration (weeks): 8

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission
Response

Study F1J-MC-HMAQ-Study Group Ba

RCT

Outpatient

N=119

Baseline severity: More severe

Mean age (years): 39.8

Sex (% female): NR

Ethnicity (% BME): NR

Duloxetine 40-120mg/day

Fluoxetine 20mg/day

Treatment duration (weeks): 10

Outcomes (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score
Remission
Response

Tylee 1997

RCT

Outpatient

N=341

Baseline severity: More severe

Mean age (years): 44.5

Sex (% female): 71

Ethnicity (% BME): NR

Venlafaxine 75mg/day

Fluoxetine 20mg/day

Treatment duration (weeks): 12

Outcomes (for inpatient versus outpatient subgroup analysis):

Remission
Response

VEN XR 367 (FDA)^a

RCT

Europe

Outpatient

N=246

Baseline severity: More severe

Mean age (years): NR

Sex (% female): 59

Ethnicity (% BME): NR

Venlafaxine 75mg/day or 150mg/day

Paroxetine 20mg/day

Treatment duration (weeks): 8

Outcome (for inpatient versus outpatient subgroup analysis):

Depression symptoms change score

Wade 2007

RCT

Belgium, Canada, the Czech Republic, France, Germany, Italy, Spain, Sweden & UK

Outpatient

N=295

Baseline severity: More severe

Mean age (years): 43.9

Sex (% female): 72

Ethnicity (% BME): 4

Duloxetine 60mg/day

Escitalopram 20mg/day

Treatment duration (weeks): 24

Outcomes (for inpatient versus outpatient subgroup analysis):

Remission
Response

a: Three-armed trial but where possible the demographics reported here are for only the two relevant arms.
: BME: black, minority, ethnic; mg: milligrams; N: number of participants; NR: not reported; RCT: randomised controlled trial.

From: Service delivery Models and settings for delivery of services

Cover of Service delivery Models and settings for delivery of services

Service delivery Models and settings for delivery of services: Depression in adults: Evidence review A.

NICE Guideline, No. 222.

London: National Institute for Health and Care Excellence (NICE); 2022 Jun.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.